免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 韩国三级做爰高潮HD电影 | 精品国自产拍在线观看 | 国产精品人妻无码一区二区三区牛牛 | 久久人妻熟女一区二区 | 色欲98AⅤ蜜臀| 曰韩伦理片 | 91精品国产一区二区三区香蕉 | 另类TS人妖一区二区三区 | 国产二三区 | 国产成人精品三级麻豆 | 亚洲av在线观看 | 日韩中文字幕无码 | 精品成人无码久久久久久 | 一区免费视频 | 性影院内射一区 | 精品传媒一区二区三区A片 无码人妻精品一区二区三区不卡 | 国产精品国产成人国产三级 | 国产无套内射普通话对白 | 亚洲精品乱码一品二品三品欧美 | 久久激情五月天 | 国产25页 | 91精品免费 | 日韩AV无码区二三区A片噜大师 | 精品人妻一区二区三区日产乱码 | 国产乱伦无码视频 | 精品人妻伦一二三区久久春菊 | 无套内射视频 | av高清无码在线观看 | 三级片免费电影 | 中文字幕人妻丝袜乱一区三区 | 波多野结av衣东京热无码专区 | 91精品久久香蕉国产国二厂线看 | 91人妻人人澡人人爽人人精品 | 国产麻豆剧传媒精品国产AV杜鹃 | 国产91精品人妻互换在线 | 国产综合另类色情亚洲中出 | 一区二区三区成人视频 | 欧美成人免费专区精品高清 | 亚洲无码不卡在线观看 | 东京热高清无码 | 一区二区视频在线观看 |